|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot or qRT-PCR was used to analyze the effect of NEK2 on the phosphorylation levels of ERK and c-JUN in two GC cell lines (BGC823 and SGC7901) with NEK2 overexpression, and the expression of the downstream effector cyclin D1.
|
31249448 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
As cyclin D1 and vimentin play an oncogenic role in gastric cancer, CORO1C may exert its tumor-promoting activity through these proteins.
|
30974047 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The recovered CCND1 expression counteracted the effects of miR-623 on GC cell proliferation, chemosensitivity, and 5-FU-induced apoptosis.
|
29495973 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Utilizing MTT, clonogenic, flow cytometry, wound healing and Transwell invasion assays in addition to Western blotting, the present study demonstrated that the overexpression of T-cad suppressed GC cell growth and colony formation via cell cycle arrest at the G0/G1 phase via downregulating the expression of cyclin dependent kinase 4 and Cyclin D1.
|
29104635 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated that UCA1 as a critical regulator involved in GC proliferation and cell cycle progression by promoting cyclin D1 expression, which indicates that it may be clinically a potential therapeutic target in GC.
|
28569779 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of miR-143 inhibited cell proliferation, invasion, S phase cell proportion and cell cycle related protein levels of Cyclin D1, CDK4 and CDK6 in GC.
|
28718369 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When stratifying by the type, Sex and H. pylori infection in dominant model, Interestingly, we found the opposite result in Male (AA + GA vs. GG: OR=0.5, 95% CI=0.33-0.76, P=0.001), there were no association between CCND1 G870A polymorphism and GC risk in any other subgroup.
|
27623072 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier method and cox proportional hazards model were used to analyze the relationship of HOXA1 and cyclin D1 expression with GC clinical outcomes.
|
26791264 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
|
27798882 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further mechanism study indicated that CCND1 was a direct target of miR-193b in GC.
|
27071318 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and downregulated cyclin D1 and MMP-9 expression in these GC cell lines.
|
25586465 |
2015 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%).
|
25882375 |
2015 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
|
25649416 |
2015 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1.
|
24623314 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no such association of CCND1 G1722C with gastric cancer.
|
25202078 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since overexpressed cyclin D1 is closely related to human gastric cancer progression, inhibition of cyclin D1 using specific targeting could be an effective treatment method of human gastric cancer.
|
24618206 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the correlation of RKIP, STAT3 and cyclin D1 expression in the tumorigenesis of gastric cancer.
|
25337233 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, β-cryptoxanthin induced an accumulation of cells in the G1/G0 phase of the cell cycle (as detected by flow cytometry), which was in accordance with an increased expression of p21 and down regulations of cyclin D1 and cyclin E, detected by Western blot analysis, and β-cryptoxanthin increased the mRNA levels of retinoic acid receptor β (RARβ) with the treatment at 10 μM for 24 h. Collectively, the above findings suggest that β-cryptoxanthin could be therapeutic in the treatment of stomach cancer cell in vitro.
|
23194503 |
2013 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil.
|
24100731 |
2013 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that miR-9 suppresses the expression of cyclin D1 and Ets1 via the binding sites in their 3'-UTR, thus inhibiting the proliferation, invasion and metastasis of gastric cancer.
|
23383271 |
2013 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
The gastric cancer incidence and expression of cyclin D1/ckd4 in gastric carcinogenesis were significantly higher in males than females.
|
21628965 |
2011 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of CCND1 is associated with CIHM status in gastric cancer, especially in the advanced stage, but is independent of clinico-pathological features.
|
20397048 |
2010 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CCND1 genotype distribution among the patients was significantly different from that among controls; AA (odds ratio (OR)=0.348, 95% CI: 0.163-0.742) and GA (OR=0.715, 95% CI: 0.506-1.012) genotypes were significantly lower in the gastric cancer patients than in the controls when subjects with the GG genotype served as the reference category.
|
18609126 |
2008 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients.
|
17447856 |
2007 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data indicated an association with alcohol consumption and the CCND1 gene or protein levels, in both esophageal and gastric cancers.
|
16490596 |
2006 |